AMPH STOCK ALERT: Levi & Korsinsky Notifies Amphastar Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential violations of federal securities laws. This follows the FDA's secondary complete response letter regarding Amphastar's generic teriparatide ANDA, AMP-015.
February 27, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations. This comes after the FDA issued a secondary complete response letter for Amphastar's generic teriparatide ANDA, AMP-015.
The investigation by Levi & Korsinsky into potential securities law violations is significant for Amphastar Pharmaceuticals, as it could lead to legal and financial repercussions. The FDA's secondary complete response letter indicates regulatory challenges, which may negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100